The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Generic Injectables Market Research Report 2024
Synopsis
Generic injectables refer to sterile solutions (including emulsions and suspensions) made of drugs for injection into the body, and sterile powders or concentrated solutions that are prepared into solutions or suspensions before use.
The injection is fast and reliable, not affected by pH, enzymes, food, etc., has no first-pass effect, and can play a systemic or local positioning effect. It is suitable for patients who are not suitable for oral medicine and patients who cannot be taken orally. However, the development and production process of injections is complicated and safe. The body has poor adaptability and high cost.
The global Generic Injectables market was valued at US$ 30610 million in 2023 and is anticipated to reach US$ 39060 million by 2030, witnessing a CAGR of 3.5% during the forecast period 2024-2030.
In the segment of generic sterile injectables, the Hospira (Pfizer Inc.) is the largest player, and Fresenius Kabi is the second. Top two players hold a share about 27% in 2019. The US market is dominated by two players like Hospira (Pfizer Inc.), Fresenius Kabi, Sandoz (Novartis), Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd, Grifols, Nichi-Iko Group (Sagent), Teva Pharmaceutical, Auromedics, Sanofi, Gland Pharma and Endo International PLC.
This report aims to provide a comprehensive presentation of the global market for Generic Injectables, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Generic Injectables.
Report Scope
The Generic Injectables market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Generic Injectables market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Generic Injectables companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Hospira (Pfizer Inc.)
Fresenius Kabi
Sandoz (Novartis)
Hikma Pharmaceuticals PLC
Dr. Reddy’s Laboratories Ltd
Grifols
Nichi-Iko Group (Sagent)
Teva Pharmaceutical
Auromedics
Sanofi
Gland Pharma
Endo International PLC
Segment by Type
Small Molecule
Large Molecule
Segment by Application
Oncology
Anesthesia
Anti-Infectives
Parenteral Nutrition
Cardiovascular Diseases
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Generic Injectables companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Generic injectables refer to sterile solutions (including emulsions and suspensions) made of drugs for injection into the body, and sterile powders or concentrated solutions that are prepared into solutions or suspensions before use.
The injection is fast and reliable, not affected by pH, enzymes, food, etc., has no first-pass effect, and can play a systemic or local positioning effect. It is suitable for patients who are not suitable for oral medicine and patients who cannot be taken orally. However, the development and production process of injections is complicated and safe. The body has poor adaptability and high cost.
The global Generic Injectables market was valued at US$ 30610 million in 2023 and is anticipated to reach US$ 39060 million by 2030, witnessing a CAGR of 3.5% during the forecast period 2024-2030.
In the segment of generic sterile injectables, the Hospira (Pfizer Inc.) is the largest player, and Fresenius Kabi is the second. Top two players hold a share about 27% in 2019. The US market is dominated by two players like Hospira (Pfizer Inc.), Fresenius Kabi, Sandoz (Novartis), Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd, Grifols, Nichi-Iko Group (Sagent), Teva Pharmaceutical, Auromedics, Sanofi, Gland Pharma and Endo International PLC.
This report aims to provide a comprehensive presentation of the global market for Generic Injectables, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Generic Injectables.
Report Scope
The Generic Injectables market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Generic Injectables market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Generic Injectables companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Hospira (Pfizer Inc.)
Fresenius Kabi
Sandoz (Novartis)
Hikma Pharmaceuticals PLC
Dr. Reddy’s Laboratories Ltd
Grifols
Nichi-Iko Group (Sagent)
Teva Pharmaceutical
Auromedics
Sanofi
Gland Pharma
Endo International PLC
Segment by Type
Small Molecule
Large Molecule
Segment by Application
Oncology
Anesthesia
Anti-Infectives
Parenteral Nutrition
Cardiovascular Diseases
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Generic Injectables companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Generic Injectables Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Small Molecule
1.2.3 Large Molecule
1.3 Market by Application
1.3.1 Global Generic Injectables Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Oncology
1.3.3 Anesthesia
1.3.4 Anti-Infectives
1.3.5 Parenteral Nutrition
1.3.6 Cardiovascular Diseases
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Generic Injectables Market Perspective (2019-2030)
2.2 Generic Injectables Growth Trends by Region
2.2.1 Global Generic Injectables Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Generic Injectables Historic Market Size by Region (2019-2024)
2.2.3 Generic Injectables Forecasted Market Size by Region (2025-2030)
2.3 Generic Injectables Market Dynamics
2.3.1 Generic Injectables Industry Trends
2.3.2 Generic Injectables Market Drivers
2.3.3 Generic Injectables Market Challenges
2.3.4 Generic Injectables Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Generic Injectables Players by Revenue
3.1.1 Global Top Generic Injectables Players by Revenue (2019-2024)
3.1.2 Global Generic Injectables Revenue Market Share by Players (2019-2024)
3.2 Global Generic Injectables Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Generic Injectables Revenue
3.4 Global Generic Injectables Market Concentration Ratio
3.4.1 Global Generic Injectables Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Generic Injectables Revenue in 2023
3.5 Generic Injectables Key Players Head office and Area Served
3.6 Key Players Generic Injectables Product Solution and Service
3.7 Date of Enter into Generic Injectables Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Generic Injectables Breakdown Data by Type
4.1 Global Generic Injectables Historic Market Size by Type (2019-2024)
4.2 Global Generic Injectables Forecasted Market Size by Type (2025-2030)
5 Generic Injectables Breakdown Data by Application
5.1 Global Generic Injectables Historic Market Size by Application (2019-2024)
5.2 Global Generic Injectables Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Generic Injectables Market Size (2019-2030)
6.2 North America Generic Injectables Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Generic Injectables Market Size by Country (2019-2024)
6.4 North America Generic Injectables Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Generic Injectables Market Size (2019-2030)
7.2 Europe Generic Injectables Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Generic Injectables Market Size by Country (2019-2024)
7.4 Europe Generic Injectables Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Generic Injectables Market Size (2019-2030)
8.2 Asia-Pacific Generic Injectables Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Generic Injectables Market Size by Region (2019-2024)
8.4 Asia-Pacific Generic Injectables Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Generic Injectables Market Size (2019-2030)
9.2 Latin America Generic Injectables Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Generic Injectables Market Size by Country (2019-2024)
9.4 Latin America Generic Injectables Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Generic Injectables Market Size (2019-2030)
10.2 Middle East & Africa Generic Injectables Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Generic Injectables Market Size by Country (2019-2024)
10.4 Middle East & Africa Generic Injectables Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Hospira (Pfizer Inc.)
11.1.1 Hospira (Pfizer Inc.) Company Detail
11.1.2 Hospira (Pfizer Inc.) Business Overview
11.1.3 Hospira (Pfizer Inc.) Generic Injectables Introduction
11.1.4 Hospira (Pfizer Inc.) Revenue in Generic Injectables Business (2019-2024)
11.1.5 Hospira (Pfizer Inc.) Recent Development
11.2 Fresenius Kabi
11.2.1 Fresenius Kabi Company Detail
11.2.2 Fresenius Kabi Business Overview
11.2.3 Fresenius Kabi Generic Injectables Introduction
11.2.4 Fresenius Kabi Revenue in Generic Injectables Business (2019-2024)
11.2.5 Fresenius Kabi Recent Development
11.3 Sandoz (Novartis)
11.3.1 Sandoz (Novartis) Company Detail
11.3.2 Sandoz (Novartis) Business Overview
11.3.3 Sandoz (Novartis) Generic Injectables Introduction
11.3.4 Sandoz (Novartis) Revenue in Generic Injectables Business (2019-2024)
11.3.5 Sandoz (Novartis) Recent Development
11.4 Hikma Pharmaceuticals PLC
11.4.1 Hikma Pharmaceuticals PLC Company Detail
11.4.2 Hikma Pharmaceuticals PLC Business Overview
11.4.3 Hikma Pharmaceuticals PLC Generic Injectables Introduction
11.4.4 Hikma Pharmaceuticals PLC Revenue in Generic Injectables Business (2019-2024)
11.4.5 Hikma Pharmaceuticals PLC Recent Development
11.5 Dr. Reddy’s Laboratories Ltd
11.5.1 Dr. Reddy’s Laboratories Ltd Company Detail
11.5.2 Dr. Reddy’s Laboratories Ltd Business Overview
11.5.3 Dr. Reddy’s Laboratories Ltd Generic Injectables Introduction
11.5.4 Dr. Reddy’s Laboratories Ltd Revenue in Generic Injectables Business (2019-2024)
11.5.5 Dr. Reddy’s Laboratories Ltd Recent Development
11.6 Grifols
11.6.1 Grifols Company Detail
11.6.2 Grifols Business Overview
11.6.3 Grifols Generic Injectables Introduction
11.6.4 Grifols Revenue in Generic Injectables Business (2019-2024)
11.6.5 Grifols Recent Development
11.7 Nichi-Iko Group (Sagent)
11.7.1 Nichi-Iko Group (Sagent) Company Detail
11.7.2 Nichi-Iko Group (Sagent) Business Overview
11.7.3 Nichi-Iko Group (Sagent) Generic Injectables Introduction
11.7.4 Nichi-Iko Group (Sagent) Revenue in Generic Injectables Business (2019-2024)
11.7.5 Nichi-Iko Group (Sagent) Recent Development
11.8 Teva Pharmaceutical
11.8.1 Teva Pharmaceutical Company Detail
11.8.2 Teva Pharmaceutical Business Overview
11.8.3 Teva Pharmaceutical Generic Injectables Introduction
11.8.4 Teva Pharmaceutical Revenue in Generic Injectables Business (2019-2024)
11.8.5 Teva Pharmaceutical Recent Development
11.9 Auromedics
11.9.1 Auromedics Company Detail
11.9.2 Auromedics Business Overview
11.9.3 Auromedics Generic Injectables Introduction
11.9.4 Auromedics Revenue in Generic Injectables Business (2019-2024)
11.9.5 Auromedics Recent Development
11.10 Sanofi
11.10.1 Sanofi Company Detail
11.10.2 Sanofi Business Overview
11.10.3 Sanofi Generic Injectables Introduction
11.10.4 Sanofi Revenue in Generic Injectables Business (2019-2024)
11.10.5 Sanofi Recent Development
11.11 Gland Pharma
11.11.1 Gland Pharma Company Detail
11.11.2 Gland Pharma Business Overview
11.11.3 Gland Pharma Generic Injectables Introduction
11.11.4 Gland Pharma Revenue in Generic Injectables Business (2019-2024)
11.11.5 Gland Pharma Recent Development
11.12 Endo International PLC
11.12.1 Endo International PLC Company Detail
11.12.2 Endo International PLC Business Overview
11.12.3 Endo International PLC Generic Injectables Introduction
11.12.4 Endo International PLC Revenue in Generic Injectables Business (2019-2024)
11.12.5 Endo International PLC Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Generic Injectables Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Small Molecule
Table 3. Key Players of Large Molecule
Table 4. Global Generic Injectables Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global Generic Injectables Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Generic Injectables Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Generic Injectables Market Share by Region (2019-2024)
Table 8. Global Generic Injectables Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Generic Injectables Market Share by Region (2025-2030)
Table 10. Generic Injectables Market Trends
Table 11. Generic Injectables Market Drivers
Table 12. Generic Injectables Market Challenges
Table 13. Generic Injectables Market Restraints
Table 14. Global Generic Injectables Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Generic Injectables Market Share by Players (2019-2024)
Table 16. Global Top Generic Injectables Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Generic Injectables as of 2023)
Table 17. Ranking of Global Top Generic Injectables Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by Generic Injectables Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Generic Injectables Product Solution and Service
Table 21. Date of Enter into Generic Injectables Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Generic Injectables Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Generic Injectables Revenue Market Share by Type (2019-2024)
Table 25. Global Generic Injectables Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Generic Injectables Revenue Market Share by Type (2025-2030)
Table 27. Global Generic Injectables Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Generic Injectables Revenue Market Share by Application (2019-2024)
Table 29. Global Generic Injectables Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Generic Injectables Revenue Market Share by Application (2025-2030)
Table 31. North America Generic Injectables Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America Generic Injectables Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America Generic Injectables Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe Generic Injectables Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe Generic Injectables Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe Generic Injectables Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific Generic Injectables Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific Generic Injectables Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific Generic Injectables Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America Generic Injectables Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America Generic Injectables Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America Generic Injectables Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa Generic Injectables Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa Generic Injectables Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa Generic Injectables Market Size by Country (2025-2030) & (US$ Million)
Table 46. Hospira (Pfizer Inc.) Company Detail
Table 47. Hospira (Pfizer Inc.) Business Overview
Table 48. Hospira (Pfizer Inc.) Generic Injectables Product
Table 49. Hospira (Pfizer Inc.) Revenue in Generic Injectables Business (2019-2024) & (US$ Million)
Table 50. Hospira (Pfizer Inc.) Recent Development
Table 51. Fresenius Kabi Company Detail
Table 52. Fresenius Kabi Business Overview
Table 53. Fresenius Kabi Generic Injectables Product
Table 54. Fresenius Kabi Revenue in Generic Injectables Business (2019-2024) & (US$ Million)
Table 55. Fresenius Kabi Recent Development
Table 56. Sandoz (Novartis) Company Detail
Table 57. Sandoz (Novartis) Business Overview
Table 58. Sandoz (Novartis) Generic Injectables Product
Table 59. Sandoz (Novartis) Revenue in Generic Injectables Business (2019-2024) & (US$ Million)
Table 60. Sandoz (Novartis) Recent Development
Table 61. Hikma Pharmaceuticals PLC Company Detail
Table 62. Hikma Pharmaceuticals PLC Business Overview
Table 63. Hikma Pharmaceuticals PLC Generic Injectables Product
Table 64. Hikma Pharmaceuticals PLC Revenue in Generic Injectables Business (2019-2024) & (US$ Million)
Table 65. Hikma Pharmaceuticals PLC Recent Development
Table 66. Dr. Reddy’s Laboratories Ltd Company Detail
Table 67. Dr. Reddy’s Laboratories Ltd Business Overview
Table 68. Dr. Reddy’s Laboratories Ltd Generic Injectables Product
Table 69. Dr. Reddy’s Laboratories Ltd Revenue in Generic Injectables Business (2019-2024) & (US$ Million)
Table 70. Dr. Reddy’s Laboratories Ltd Recent Development
Table 71. Grifols Company Detail
Table 72. Grifols Business Overview
Table 73. Grifols Generic Injectables Product
Table 74. Grifols Revenue in Generic Injectables Business (2019-2024) & (US$ Million)
Table 75. Grifols Recent Development
Table 76. Nichi-Iko Group (Sagent) Company Detail
Table 77. Nichi-Iko Group (Sagent) Business Overview
Table 78. Nichi-Iko Group (Sagent) Generic Injectables Product
Table 79. Nichi-Iko Group (Sagent) Revenue in Generic Injectables Business (2019-2024) & (US$ Million)
Table 80. Nichi-Iko Group (Sagent) Recent Development
Table 81. Teva Pharmaceutical Company Detail
Table 82. Teva Pharmaceutical Business Overview
Table 83. Teva Pharmaceutical Generic Injectables Product
Table 84. Teva Pharmaceutical Revenue in Generic Injectables Business (2019-2024) & (US$ Million)
Table 85. Teva Pharmaceutical Recent Development
Table 86. Auromedics Company Detail
Table 87. Auromedics Business Overview
Table 88. Auromedics Generic Injectables Product
Table 89. Auromedics Revenue in Generic Injectables Business (2019-2024) & (US$ Million)
Table 90. Auromedics Recent Development
Table 91. Sanofi Company Detail
Table 92. Sanofi Business Overview
Table 93. Sanofi Generic Injectables Product
Table 94. Sanofi Revenue in Generic Injectables Business (2019-2024) & (US$ Million)
Table 95. Sanofi Recent Development
Table 96. Gland Pharma Company Detail
Table 97. Gland Pharma Business Overview
Table 98. Gland Pharma Generic Injectables Product
Table 99. Gland Pharma Revenue in Generic Injectables Business (2019-2024) & (US$ Million)
Table 100. Gland Pharma Recent Development
Table 101. Endo International PLC Company Detail
Table 102. Endo International PLC Business Overview
Table 103. Endo International PLC Generic Injectables Product
Table 104. Endo International PLC Revenue in Generic Injectables Business (2019-2024) & (US$ Million)
Table 105. Endo International PLC Recent Development
Table 106. Research Programs/Design for This Report
Table 107. Key Data Information from Secondary Sources
Table 108. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Generic Injectables Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Generic Injectables Market Share by Type: 2023 VS 2030
Figure 3. Small Molecule Features
Figure 4. Large Molecule Features
Figure 5. Global Generic Injectables Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global Generic Injectables Market Share by Application: 2023 VS 2030
Figure 7. Oncology Case Studies
Figure 8. Anesthesia Case Studies
Figure 9. Anti-Infectives Case Studies
Figure 10. Parenteral Nutrition Case Studies
Figure 11. Cardiovascular Diseases Case Studies
Figure 12. Generic Injectables Report Years Considered
Figure 13. Global Generic Injectables Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 14. Global Generic Injectables Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Generic Injectables Market Share by Region: 2023 VS 2030
Figure 16. Global Generic Injectables Market Share by Players in 2023
Figure 17. Global Top Generic Injectables Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Generic Injectables as of 2023)
Figure 18. The Top 10 and 5 Players Market Share by Generic Injectables Revenue in 2023
Figure 19. North America Generic Injectables Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. North America Generic Injectables Market Share by Country (2019-2030)
Figure 21. United States Generic Injectables Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Canada Generic Injectables Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Generic Injectables Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Generic Injectables Market Share by Country (2019-2030)
Figure 25. Germany Generic Injectables Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. France Generic Injectables Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. U.K. Generic Injectables Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Italy Generic Injectables Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Russia Generic Injectables Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Nordic Countries Generic Injectables Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Generic Injectables Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Generic Injectables Market Share by Region (2019-2030)
Figure 33. China Generic Injectables Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Japan Generic Injectables Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. South Korea Generic Injectables Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Southeast Asia Generic Injectables Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. India Generic Injectables Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Australia Generic Injectables Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Generic Injectables Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Generic Injectables Market Share by Country (2019-2030)
Figure 41. Mexico Generic Injectables Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Brazil Generic Injectables Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Generic Injectables Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Generic Injectables Market Share by Country (2019-2030)
Figure 45. Turkey Generic Injectables Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Saudi Arabia Generic Injectables Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Hospira (Pfizer Inc.) Revenue Growth Rate in Generic Injectables Business (2019-2024)
Figure 48. Fresenius Kabi Revenue Growth Rate in Generic Injectables Business (2019-2024)
Figure 49. Sandoz (Novartis) Revenue Growth Rate in Generic Injectables Business (2019-2024)
Figure 50. Hikma Pharmaceuticals PLC Revenue Growth Rate in Generic Injectables Business (2019-2024)
Figure 51. Dr. Reddy’s Laboratories Ltd Revenue Growth Rate in Generic Injectables Business (2019-2024)
Figure 52. Grifols Revenue Growth Rate in Generic Injectables Business (2019-2024)
Figure 53. Nichi-Iko Group (Sagent) Revenue Growth Rate in Generic Injectables Business (2019-2024)
Figure 54. Teva Pharmaceutical Revenue Growth Rate in Generic Injectables Business (2019-2024)
Figure 55. Auromedics Revenue Growth Rate in Generic Injectables Business (2019-2024)
Figure 56. Sanofi Revenue Growth Rate in Generic Injectables Business (2019-2024)
Figure 57. Gland Pharma Revenue Growth Rate in Generic Injectables Business (2019-2024)
Figure 58. Endo International PLC Revenue Growth Rate in Generic Injectables Business (2019-2024)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
